FDA: Eisai ‘s “Rembima” approved as a hepatocellular cancer drug

By Cancer, FDA, Pharmaceutical

FDA: Eisai ‘s “Rembima” approved as a hepatocellular cancer drug

The US Food and Drug Administration (FDA) approved Eisai’s (4523.T) anti-cancer drug “Rembima” as a drug for hepatocellular cancer (HCC) on 16th.

This was approved based on clinical trials for patients with unresectable hepatocellular carcinoma.

Already, the company has obtained similar approval in Japan this March.

In March, Eisai has a strategic alliance with Merck (MRK.N) in the area of anti-cancer joint development and co-promotion.

Reuters

https://jp.reuters.com/article/eisai-fda-idJPKBN1L207Y?il=0

More from tokioX :

  1. Selling price for Lecanemab: $26,500 per patient per year!
  2. US FDA: Takeda Pharmaceutical’s Lung Cancer Treatment Approval: Exkivity
  3. Kyowa Kirin Announces FDA Approval of NOURIANZTM (istradefylline) for Use in Parkinson’s Disease
  4. 💊FDA & PHARMA TODAY
  5. 💊Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)
  6. 💊FDA PHARMA today
  7. 💊FDA PHARMA updates